

# Cancer Immunology Immunotherapy

Founding Editor  
G. Mathé

Other Biological Response Modifications

Volume 18 1984

## Editors in Chief

R. W. Baldwin E. Mihich

## Editorial Board

E. C. Borden Madison

P. Burtin Vlillejuif

M. Cheever Seattle

G. A. Currie Oxted Surrey

G. Della Porta Milano

J. E. de Vries Amsterdam

S. Dray Chicago

S. Ferrone Valhalla

A. Goldstein Washington

K. Hellstrom Seattle

R. Herberman Bethesda

L. Israël Bobigny

K. Karrer Vienna

E. Klein Stockholm

H. Kobayashi Sapporo

M. Mastrangelo Philadelphia

W. H. McBride Edinburgh

P. Minden Denver

M. Mitchell Los Angeles

R. J. North Saranac Lake

H. M. Pinedo Amsterdam

R. Oldham Vancouver

H. Ozer Buffalo

P. Reizenstein Stockholm

M. Rittenberg Portland

V. Schirrmacher Heidelberg

B. Serrou Montpellier

F. Spreafico Milan

J. Stjernswärd Geneva

B. Vose Cheshire

N. Warner Mountain View

D. Weiss Jerusalem

Y. Yagi Kamakura City

K. Yamamoto Kanazawa

Y. Yamamura Osaka



Springer International

# Cancer Immunology Immunotherapy

Founding Editor  
G. Mathé

Other Biological Response Modifications

Volume 18 1984

## Editors in Chief

R. W. Baldwin E. Mihich

## Editorial Board

E. C. Borden Madison

P. Burtin Vlillejuif

M. Cheever Seattle

G. A. Currie Oxted Surrey

G. Della Porta Milano

J. E. de Vries Amsterdam

S. Dray Chicago

S. Ferrone Valhalla

A. Goldstein Washington

K. Hellstrom Seattle

R. Herberman Bethesda

L. Israël Bobigny

K. Karrer Vienna

E. Klein Stockholm

H. Kobayashi Sapporo

M. Mastrangelo Philadelphia

W. H. McBride Edinburgh

P. Minden Denver

M. Mitchell Los Angeles

R. J. North Saranac Lake

H. M. Pinedo Amsterdam

R. Oldham Vancouver

H. Ozer Buffalo

P. Reizenstein Stockholm

M. Rittenberg Portland

V. Schirrmacher Heidelberg

B. Serrou Montpellier

F. Spreafico Milan

J. Stjernswärd Geneva

B. Vose Cheshire

N. Warner Mountain View

D. Weiss Jerusalem

Y. Yagi Kamakura City

K. Yamamoto Kanazawa

Y. Yamamura Osaka



Springer International

## Volume 18 – Subject index

### A

- Acyliptipeptide 169
- Adherent cells 179
- AIDS 141
- Antibody
  - anti-tumoral monoclonal 19
  - dependent cellular cytotoxicity 54
  - linked muramyl dipeptide 155
- Antigen
  - human leukocyte 91
  - tumor 195, 203, 215
- Antiperinuclear factor 80

### Anti-tumor

- activity 29
- agent 164

### C

- Cefotaxime 164
- Chemoimmunotherapy 149
- Chemotaxis 223
- cis-platin 223
- Clindamycin 164
- Contact sensitivity 135
- Cyclophosphamide 113
- Cytokines 135
- Cytotoxicity
  - antibody dependent cellular 54
  - cells 195
  - Kupffer cells 118
  - lymphocytes 126, 174, 179

### E

- Endotoxin 75, 107

### G

- Gastric cancer 13

### H

- HLA 91

### I

- Immune-complexes 29
- Immunity
  - concomitant 75
  - natural 35
  - T cell-mediated 69
  - tumor 69
- Immunomodulation 123, 185
- Immunosuppressive factor 101
- Immunotherapy 1, 5, 13, 49, 82, 107, 149, 185

### K

- Kupffer cells 118

### L

- Leukemia 91
  - acute nonlymphocytic 149
  - Friend virus 35
  - L1210 101

### Leukocyte adherence inhibition 59

- Levamisole 13
- Lipid A 107
- Liposomes 123
- L-PAM 41
- Lung carcinoma 24, 80, 82
  - Lewis lung 19
- Lymphocyte
  - cytotoxic 126
  - large granular 5
  - stimulation 101, 126
  - T 141
- Lymphoid cells, tumor infiltrating 174, 179

### M

- Macrophages 135, 155, 160, 169
- Mammary carcinoma 49, 174, 179
- Melanoma
  - B16 195, 209
- Metastasis 185, 209
- Mezlocillian 164
- Monoclonal antibody 19, 155
- Monocytes 223
- MOPC-315 tumor 41
- Muramyl dipeptide 123
  - antibody linked 155
- Mycosis fungoides 138
- Myelopoiesis 226

### N

- Natural immunity 35, 138

### O

- OK 432 5

### P

- Peptidoglycan 49
- Piperacillin 164
- Propionbacterium acnes* 87
- Protein A 29
- PSK 149, 160

### T

- T cell 135, 141, 174, 179, 195
  - growth factor 215
  - mediated immunity 126, 160
  - subsets 69, 75
  - suppressor 113
- Tetraphenylphosphonium 59
- Thymosin fraction five 185
- Thymus 24
- Transmembrane potential 59
- Tumor
  - antigen 203, 215
  - imaging 19
  - immunity 69, 75
  - immunogenicity 1
  - necrosis factor 87